Disclosure: Delivra Health Brands Inc. has paid FRC a fee for research coverage and distribution of reports. See last page for other important disclosures, rating, and risk definitions.
The analyst’s rating and fair value are one click away. Free FRC account, no credit card.
Already have an account?
DHB’s product portfolio consists of sleep aid/anxiety relief formulations, and pain relief products. The company is also trying to license its patent-pending proprietary transdermal delivery technology platform to pharma companies.
Follows an asset-light model by outsourcing manufacturing and packaging to entities in North America. Two Primary Brands: Dream Water (sold in the U.S./Canada/the Middle East), and LivRelief (sold in Canada)
Available at 30k+ outlets in the U.S., and Canada, including major retailers and pharmacy chains. DHB’s annual revenue per store is approximately $350, which we believe is on the higher end of small health and wellness companies; larger brands generate $1k+
In FY2024, revenue was up 26% YoY, coming in just 0.5% below our estimate, driven by strong Dream Water sales in the U.S. Gross margins were up 1 pp, aligning with our estimate
Marketing expenses increased 5 pp YoY to 13% of revenue, aligning with our estimate, but remained significantly lower than the 20%-35% range of comparables (Source: S&P Capital IQ
We believe the company will raise its marketing budget to remain competitive with its peers. SG&A expenses were up 8% YoY, and 10% higher than our estimate due to higher head count
EBITDA was up 68% YoY, and net loss decreased, while FCF turned positive due to higher revenue. Adjusted EPS was 31% lower than our estimate due to higher SG&A expenses . Debt/Capital decreased due to higher retained earnings
It is estimated that the global sleep aids market will grow from US$59B in 2023, to US$64B in 2024, and to US$89B by 2030, reflecting a CAGR of 6% (2023-2030)
It is estimated that the global pain management therapeutics market will grow from US$85B in 2024, to US$123B by 2034, reflecting a CAGR of 4%
We are maintaining our revenue forecasts, while raising SG&A expenses, resulting in lower EPS estimates
As a result, our DCF valuation changed slightly from $0.10 to $0.095/share
We are reiterating our BUY rating, and raising our fair value estimate from $0.08 to $0.09/share (the average of our DCF and comparables valuations). Shares are trading at a 95% discount relative to the average sector EV/Revenue of 3.1x. Given the growing demand for natural health and wellness products, we believe DHB's focus on sleep aids and pain relief aligns with a significant market trend.
The average sector forward EV/Revenue is up 11% since our previous report in May 2024. DHB is trading at a 90% discount (previously 21%) relative to its comparables. Using the average sector EV/Revenue, we arrived at a comparables valuation of $0.08/share (previously $0.06/share)
We believe the company is exposed to the following key risks (not exhaustive):
